Literature DB >> 1906398

Lithotripsy versus cholecystectomy for management of gallstones. A decision analysis by Markov process.

A Sonnenberg1, G A Derfus, K H Soergel.   

Abstract

Extracorporeal shock-wave lithotripsy is a new treatment method that effectively distintegrates radiolucent gallstones and is associated with a low complication rate. Using the model of a Markov process for decision analysis, survival and costs under four possible strategies to treat gallstones were compared: expectant management with cholecystectomy (EC) or lithotripsy (EL) reserved for symptomatic gallstones; prophylactic cholecystectomy (PC) or lithotripsy (PL) for all gallstones. Life expectancy for the different strategies varies by few days. Only if high annual rates of pain and complication occurred in subjects with silent gallstones would both prophylactic procedures marginally increase life expectancy. Prophylactic cholecystectomy then would be more cost-effective than prophylactic lithotripsy. Expectant strategies remain much cheaper than prophylactic management over a broad range of probability values and procedural costs. Expectant use of lithotripsy costs less than cholecystectomy. A low success rate of lithotripsy would raise the direct costs of lithotripsy above those of cholecystectomy but leave total costs of both strategies in the same order of magnitude. Lithotripsy appears to be a feasible alternative to treat symptomatic but not asymptomatic gallstones.

Entities:  

Mesh:

Year:  1991        PMID: 1906398     DOI: 10.1007/bf01297146

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  22 in total

1.  Complications of cholelithiasis.

Authors:  H F Newman; J D Northup; M Rosenblum; H Abrams
Journal:  Am J Gastroenterol       Date:  1968-12       Impact factor: 10.864

2.  [Biliary shock-wave lithotripsy. Fragmentation and lysis--a new procedure].

Authors:  L Greiner; H Wenzel; C Jakobeit
Journal:  Dtsch Med Wochenschr       Date:  1987-12-04       Impact factor: 0.628

3.  Shock-wave lithotripsy of gallbladder stones. The first 175 patients.

Authors:  M Sackmann; M Delius; T Sauerbruch; J Holl; W Weber; E Ippisch; U Hagelauer; O Wess; W Hepp; W Brendel
Journal:  N Engl J Med       Date:  1988-02-18       Impact factor: 91.245

4.  Use of external shock-wave lithotripsy and adjuvant ursodiol for treatment of radiolucent gallstones. A national multicenter study.

Authors:  D Burnett; A Ertan; R Jones; J P O'Leary; R Mackie; J E Robinson; G Salen; L Stahlgren; D H Van Thiel; L Vassy
Journal:  Dig Dis Sci       Date:  1989-07       Impact factor: 3.199

5.  Early gallstone recurrence rate after successful shock-wave therapy.

Authors:  M Sackmann; E Ippisch; T Sauerbruch; J Holl; W Brendel; G Paumgartner
Journal:  Gastroenterology       Date:  1990-02       Impact factor: 22.682

6.  Gallstone recurrence after successful oral bile acid treatment. A 12-year follow-up study and evaluation of long-term postdissolution treatment.

Authors:  N Villanova; F Bazzoli; F Taroni; R Frabboni; G Mazzella; D Festi; L Barbara; E Roda
Journal:  Gastroenterology       Date:  1989-09       Impact factor: 22.682

7.  Gallstone recurrence after medical dissolution. An overestimated threat?

Authors:  A Lanzini; R P Jazrawi; R M Kupfer; D P Maudgal; A E Joseph; T C Northfield
Journal:  J Hepatol       Date:  1986       Impact factor: 25.083

8.  Low-dose chenodiol to prevent gallstone recurrence after dissolution therapy.

Authors:  J W Marks; S P Lan; R A Baum; R L Habig; R F Hanson; T Hersh; N C Hightower; A F Hofmann; J M Lachin; E C Lasser
Journal:  Ann Intern Med       Date:  1984-03       Impact factor: 25.391

9.  The natural history of cholelithiasis: the National Cooperative Gallstone Study.

Authors:  J L Thistle; P A Cleary; J M Lachin; M P Tyor; T Hersh
Journal:  Ann Intern Med       Date:  1984-08       Impact factor: 25.391

10.  Piezo-ceramic lithotripsy of gallbladder stones: initial experience in 38 patients.

Authors:  K A Hood; A Keightley; R H Dowling; J A Dick; C N Mallinson
Journal:  Lancet       Date:  1988-06-11       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.